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Marine organisms are constituted by materials with a vast range of properties and characteristics
that may justify their potential application within the biomedical field. Moreover, assuring the
sustainable exploitation of natural marine resources, the valorisation of residues from marine
origin, like those obtained from food processing, constitutes a highly interesting platform for
development of novel biomaterials, with both economic and environmental benefits. In this
perspective, an increasing number of different types of compounds are being isolated from
aquatic organisms and transformed into profitable products for health applications, including
controlled drug delivery and tissue engineering devices. This report reviews the work that is being
developed on the isolation and characterisation of some polysaccharides, proteins, glycosami-
noglycans and ceramics from marine raw materials. Emphasis is given to agar, alginates,
carrageenans, chitin and chitosan, among other polysaccharides, collagen, glycosaminoglycans
such as chondroitin sulphate, heparin and hyaluronic acid, calcium phosphorous compounds
and biosilica. Finally, this report ends by reviewing the application of the previously mentioned
materials on specific biomedical applications, in particular their participation on the development
of controlled drug delivery systems and tissue engineering scaffolds.
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Introduction
Marine organisms still remain a largely unexploited
resource on what concerns its biotechnology applica-
tion. Many organisms are composed by molecules and
materials exhibiting interesting characteristics and prop-
erties which constitute an inspiring reserve for the
development of novel medical orientated products.
Figure 1 illustrates some interesting architectures that
can be found in marine environments, inspiring for the
(bio)materials scientists, but many others can be found
under the scope of marine biomimetics studies, in which
nacre is a key material.1 In this regard, the biomedical
market represents an enormous application opportunity
for many of these molecules and materials, as the
potential added value of such products can, in principle,
justify the inherent risk related with the development
and approval of such products. Furthermore, such
products would also contribute to a more sustainable
exploitation of natural resources in general and marine
resources in particular. So, the valorisation of residues
from marine origin, like for example those normally
obtained from food processing, could constitute an
interesting platform for the development of novel value
chains with economic and environmental advantages.
An increasing number of compounds are currently
being isolated from aquatic organisms and proposed as
novel products for health-related applications ranging
from bioactive ingredients to medical devices. The
ability to use nature as an inspiring framework for the
development of novel products is not new. In fact, a
large fraction of current pharmacopoeias derives directly
or indirectly from natural products.2 In this regard,
marine species have been a valuable resource during the
last decades for the discovery of novel active pharma-
ceutical ingredients. In terms of drug development, the
screening of marine products has involved a vast library
of biomolecules. The investigation of many of these
molecules has led to extensive preclinical studies, which
have justified, in some cases, clinical trials in several
therapeutic areas, including cancer.3–5
The exploration of marine potential on what concerns
isolation of compounds and its further use and
application in biomedical field is still in its infancy.
The number of natural derived products continues to
expand steadily in terms of number of compounds
investigated, which has been closely followed by the
increase of intellectual property, namely by the number
of patents filled.6–16 Still, to a large extend, the marine
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environment is regarded as a large untapped source of
chemical diversity.17 In fact, the harvesting of marine
potential is not limited to drug discovery alone. Al-
though the main emphasis has been given to pharma-
ceuticals, other potential applications for marine-derived
materials have been additionally explored. Biopolymers
produced by marine organisms are being increasingly
investigated for several biomedical applications.18,19
Among the many biomedical applications explored
during the last years, regenerative medicine and drug
delivery have been areas of intensive research.
This review addresses research and application devel-
opment mostly carried out during the last decade for
several marine origin materials, including polysacchar-
ides, proteins, glycosaminoglycans and ceramics. Several
aspects are covered, namely, isolation methods, main
properties and related biomedical applications, with
special emphasis to tissue engineering and drug delivery
applications.
Polysaccharides
Like their terrestrial fellows, marine organisms synthe-
sise a considerable variety of biopolymers, which can be
grouped in three main classes: polysaccharides, proteins
and nucleic acids.20 This review will focus on biopoly-
mers with structural function, namely polysaccharides
and the support protein collagen. Within polysacchar-
ides, a particular group – glycosaminoglycans (GAG) –
will be addressed in a different section, once these typi-
cally sulphated polymers, with a repeating unit con-
stituted by a hexose and a hexosamine, are synthesised
in the organism in association with proteins form-
ing the proteoglycans.21 The only exception, also later
addressed, is hyaluronic acid, which does not bear
sulphate groups nor form proteoglycans.22
Polysaccharides are biopolymers constituted by car-
bohydrate monomers (normally hexoses) linked by
glycosidic bonds. The most representative polysacchar-
ides in marine environment are agar, alginate, carragee-
nans and chitin. Chitin is, in fact, the second most
abundant biopolymer, just after cellulose. All these
polysaccharides have similar chemical structures, but the
apparently small differences are responsible for distinct
properties of the polymers. In this perspective, depend-
ing on the application envisaged for the polymer, one or
other may be selected. From all, chitin and its derivative
chitosan can be distinguished by the presence of an
amine (NH2) group, which in chitosan can be proto-
nated and thus, the polymer will bear positive charge,
while the others are neutral or negatively charged. From
the other polymers, the nature of the negative charge is
also a difference: in carrageenans, it is due to sulphate
(SO{4 ) groups and in alginate. it is due to carboxylate
(COO2) groups, while agar is neutral. Thus, if a
negatively charged polymer is needed (for interaction
with cations or positively charged polymers, for
instance), a choice can be made between alginate and
carrageenan, with the addition that negative charge
density can be tuned by pH in alginate or by type of
carrageenan (bearing different quantities of sulphate
groups per repeating unit). Considering these character-
istics, materials with different properties can be
obtained, in which gels are the paramount example. In
fact, the gelling capacity of alginate is well known, but
gels can be also obtained with carrageenans, but only
with two of the three commercial types, and the ones
1 Images of marine organisms with interesting architectures. a Crab shells and respective SEM images; b SEM image of
nacre structure, evidencing the plate-like aragonite crystals; c glass sponge (Randolph Femmer, Wikimedia Commons
2011)
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produced with kappa-carrageenan are stronger that the
ones prepared with iota-carrageenan.
In the following section, further details on each of
these biopolymers can be found, as well as a brief
reference to other less non-marine polysaccharides.
Agar
Agar is a complex polysaccharide present in the cellular
wall of red algae, namely, agarophytes, including species
belonging to the genera Gelidium and Gracilaria.23
Commercial agar is mainly extracted from species of
Gelidium, Gracilaria, Acantkopeltis, Ceramium and
Pterocladia.24
It is a structural polymer which possesses in algae a
function analogous to, but differing from, that of
cellulose in land plants. A simplified way to describe
its chemical structure is to represent agar as a
polysaccharide composed of neutral agarose and
charged agaropectin. However, a correct approach to
understand its structure is to regard agar as a complex
mixture of water-soluble galactan derivatives. It is a
typical linear (AB)n copolymer with alternating a-(1R3)
and b-(1R4) linked galactose residues.24,25 Its basic
repeat unit is recognised to be composed of 4-O-3,6-
anhydro-a-L-galactopyranose and 3-O-b-D-galactopyr-
anose, illustrated by the scheme in Fig. 2.25 Frequently,
the (1R4)-linked residues are present as the 3,6-
anhydride. The main difference between agar and
carrageenans is that (1,4)-linked residue in agar is a L-
enantiomer, whereas in carrageenans, it is a D. Its
complexity is increased by different substituents, like
methoxyl, sulphate and pyruvate groups.25,26 The pre-
sence of ester sulphate and ketal pyruvate in the back-
bone provides ionic character to the polysaccharide.27
The chemical nature of agar, including the amount and
type of substituents, will be affected by different factors
like taxa and species, environmental and physiological
conditions and extraction procedures.25
The existence of two types of agar, Gelidium and
Gracilaria agars, is now recognised. These can be
physically and chemically distinguished by their gelling
temperature and methoxyl content. However, the largest
source of agar is Gracilariales, due to its abundance and
chemical nature of the agars extracted from this red
algae order.28 Gracilaria agar gels around 40uC and has
methyl ether groups, while Gelidium agar gels at around
30uC and methyl ether substituent groups are essentially
absent.27 On the other hand, the presence of sulphate
groups in Gracilaria agars lowers their gelling ability,
when compared with Gelidium agar. This is the reason
why Gracilaria agars may be regarded as low quality. In
order to improve gelling capacity, and therefore quality,
of Gracilaria agar, it is necessary to eliminate sulphate
groups, by alkaline hydrolysis. This pre-treatment will
convert L-galactose-6-sulphate to 3,6-anhydro-L-galac-
tose, which is the main responsible for the increase in the
gel ability.28,29 Furthermore Gracilaria gels exhibit low
syneresis, when compared with Gelidium gels.28 These
inherent characteristics will govern the technical applic-
ability of these agars.
Surpassing these differences, agar typically forms soft,
thermally reversible and cation independent gels.26,27
One important property of this polysaccharide is its
ability to gel at low concentrations.24 Nowadays, the
recognised gelation mechanism involves a shift from a
random coil to double helix.27 Agar constituent poly-
saccharides, namely, agarose, play an important role
in its gel-forming characteristics. Agaropectin provides
the viscous component.30 In order to prepare an agar
aqueous solution, agar requires heating above its gel
melting point, around 85uC. Upon cooling, agar solu-
tion will settle into a soft gel. As in many polysacchar-
ides, gel-forming properties and viscosity of agar are
generally affected by different factors like chemical
substituents, sulphate content, molecular weight and
molecular weight distribution, species of alga and ex-
traction method.25,30
Applicative development of agar will depend on its
chemical composition (sulphate, methoxyl substituints
and sugar contents) which can be significantly affected
by the variables used in the extraction process.
The technology of agar production starts with pre-
treatment of the algae, extraction of agar, purification,
dehydration and desiccation (Fig. 3). The first step in
agar extraction methodology consists in bleaching off
colouring matter and elimination of lipidic matter,
which will impair polysaccharide final quality.30 Agar
is extracted by boiling the alga in water. Remarkable loss
of yield and decrease in rheological properties of the
resulting agar is usually related with elevated extraction
temperatures and prolonged extraction time.28,29 Yield
can be increased by addition of a small quantity of
phosphate, usually pyrophosphate.30 As the extract
solution cools, it will set to a gel. Purification of this gel
is made by freeze and thaw in order to eliminate water,
which contains salts, pigments and polysaccharides.24,29
One of the parameters that will define the quality of the
final extract is its rheological properties. In this sense, a
2 Structural scheme of agar exhibiting the galactopyra-
nose units
3 Schematic summary of the methodology of agar extrac-
tion from red algae
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high quality agar will form a gel, from a 1?5% solution,
with strength greater than 700 g cm22.28
Alginate
Alginate is present in the cell wall of brown algae, as
part of a wide family of glycans that compose this group
of organisms. These glycans are laminaran, cellulose,
sulphated hexouronoxylofucans, fucoidan and alginate.
Among these, alginate is quantitatively the major
polysaccharide in brown algae, building up to 45% of
the dry weight of these seaweeds. It is responsible for its
flexibility, having mechanical and structural functions as
well as ionic exchange roles.31,32 Chemical structure and
function of alginate in brown algae make it a functional
analogue of pectin of higher plants.33
The biosynthesis of this polysaccharide within brown
algae has been extensively studied and one attractive
scheme is based on D-fructose-6-P as a starting material.
Epimerisation of d-mannuronic residues, catalysed by
mannuronan C-5-epimerases, will finally lead to the
formation of alginate.33
Different structures have been proposed for this
polysaccharide, since its discovery by Stanford.
Chemically, it is now recognised as an unbranched
anionic copolymer composed of two monomers, (1R4)
linked b-D-mannuronic acid (M) and a-L-guluronic acid
(G) (Table 1).31
Both b-D-mannuronic acid and a-L-guluronic acid
are stereoisomers, differing in the configuration of the
carboxyl group, as can be seen in the chemical structure
schemed in Fig. 4. The linkage of these uronic acid
moieties is in such a way that the carboxyl group of each
unit is free, while the aldehyde group is shielded by the
glycosidic linkage. The position of each unit can vary so
they can occur in blocks of separate (M or G) or mixed
(MG) sequences.34 The relative amount of each block
type can vary between different alginates.35 This variabi-
lity at the molecular level strongly affects the physico-
chemical and reological properties of alginate.36 While
any brown algae can be used as a source of alginate,
its actual chemical structure varies from one genus to
another, and among different tissues in the algae.
Alginate quantity, composition and sequential structure
are affected by different factors, including taxa and
species, season, tissue age and type and environmental
conditions.37–41 High contents of G generally are found
in alginates prepared from stipes of old blade material
from brown algae, whereas alginates from younger
blades is characterised by low content of G-blocks and
low gel strength.41 Compositional differences between
different types of alginates reflect the relation between
structure and function. These differences are correlated
with the physico-chemical properties of alginate, which
depend on the distribution of M and G units along the
polysaccharidic chain and overall M/G ratio.31,33
Alginates rich in a-L-guluronic acid will give transpar-
ent, stiffer and more brittle gels, in the presence of
divalent cations. These types of alginate possess a low
M/G ratio.31 Alginates with higher content of b-D-
mannuronic acid or MG blocks will form flexible gels,
with low elastic moduli (Fig. 5).33,42
Gelation is an important characteristic of alginates.31
Gelation and gel physical properties are determined by
various factors, like solution viscosity, molecular weight
and molecular structure of alginate, i.e. M/G ratio and
molecular sequence, and gelation agent concentration
(e.g. calcium ions concentration).43 Alginate gels can be
formed by diverse means, namely through hydrogen
bonding at low pH or by ionic interactions with di- or
trivalent ions.42,43 G monomers play a crucial role in the
mechanism of ionic gelation of alginate, since they form
ionic bridges between different polymer chains. The
presence of divalent ions, like calcium, induces chain to
chain association in a particular manner known as the
egg-box mechanism of gelation.34,43,44 Therefore, G rich
alginate is prone to ionic gelation.43
Commercial alginates are mainly extracted from
species of Laminaria, Macrocystis, Ascophyllum, Eclo-
nia, Lessonia, Durvillea and Sargassum.45 Although algal
alginate is very well established for commercial purposes,
some bacteria are able to produce alginate-like poly-
saccharides as an extracellular material.36 Bacterial algi-
nate, produced mainly by Pseudomonas and Azotobacter,
is abundant in vegetatively growing cells and is involved
in cyst formation, protecting it from desiccation and
unfavourable conditions.36,46
There are some differences between algal and bacterial
alginate (Table 2); however, the main difference at the
molecular level is the acetylation of mannurate units in
bacterial alginate.47
The quantity and quality of the alginates extracted
from brown algae depend on different factors. A high
quality alginate forms strong gels and gives thick
aqueous solutions. A good raw material for alginate
extraction should also give a high yield of alginate.
Alginate is present in the cell wall of brown algae as
different salt forms of alginic acid, namely calcium,
Table 1 Chemical structure of alginate390
Polysaccharide Sugar units Sequence
Alginate 4-linked a-L-GulAp (#) –#-#-#-#-#-#–N-N-N-N-N-N-N-#-N-#-N–
4-linked b-D-ManAp (N)
4 Structural scheme of alginate exhibiting the mannuro-
nic and guluronic acid units
5 Dependence of alginate gel-type with chemical carbo-
hydrate sequence391
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magnesium and sodium salts, possessing different
properties.48 Thus, the extraction of alginate starts with
an acidification step, to convert all the alginate salts in
the water insoluble alginic acid form, which is more
readily extracted. The acidification step will also allow
the removal of contaminant glycans, like laminaran and
fucan.48,49 This is followed by alkaline extraction, with
sodium hydroxide solution, to convert insoluble alginic
acid to soluble sodium alginate (calcium and magnesium
salts would be insoluble), which is extracted by solid/
liquid separation, separating then the algal residue by
filtration. Finally, sodium alginate is recovered from the
aqueous solution by precipitation and is further
dryed50,51 (Fig. 6). The precipitation of sodium alginate
can be done with calcium, by acidification of the sodium
alginate solution, or with ethanol.45,52 Calcium precipi-
tation will result in fibrous calcium alginate which is
mixed with alkali slats in order to obtain sodium
alginate. Acid precipitation will result in gelatinous
alginic acid; neutralisation will render sodium alginate.
The colour of extracted alginate will depend on the used
algal raw material as well as the age of the algae.
However, the pigmentation of alginate can be controlled
by bleaching.52
A bio-refinery like concept can be applied to the
extraction of alginate, where the valorisation of different
byproducts of extraction is possible. One issue already
addressed in this regard is the study of alginate
extraction byproducts as sources of dietary fibres.49
The extraction of alginates from brown algae has been
methodically studied so as to develop economically and
industrially viable systems, with controlled properties as
to satisfy different envisaged applications.45
Carrageenan
Carrageenan represents a family of linear sulphated
polymers extracted from some species of red algae
(Rodophyta – Class Gigartinales), mainly from Chon-
drus, Eucheuma, Gigartina and Iridaea genera. The red
algae exhibit alternation of generations, and often the
different phases are isomorphic, which makes it difficult
to distinguishing them, and independent. Intra/inter-
species differences at different stages of their life cycle
often have different carrageenan types and amounts.
Besides carrageenan, which can take up to 60–80%
of its dry weight, red algae are also composed by
proteins (10–47%, with higher levels in late winter and
lower in summer), floridean starch and various com-
pounds and metabolites such as phenols, essential oils
and vitamins.53
Carrageenans are linear polymers consisting of a
backbone derived from galactose (disaccharide repeat-
ing units of alternating link 3, b-D-galactopyranose
and 4, a-D-galactopyranose) with regular but imprecise
structures, depending on the source and the conditions
of extraction/modification. There are three main types
of carrageenan, classified according to the number of
sulphate groups per disaccharide basic unit after alkaline
modification (with the conversion of precursor mole-
cules into their final commercial product): k (kappa), i
(iota) and l (lambda),54 bearing one, two and three
sulphate groups per disaccharide respectively, according
Table 2 Main differences between algal and bacterial origin alginate
Algal alginate Bacterial alginate
High variety of molar masses Higher degree of polymerisationRhigher molar masses
Alternating sequences of M and G as well as
homopolymeric monomers
Absence of oligomeric guluronic sequences
6 Schematic summary of alginate extraction
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to the schemes in Fig. 7. The largest source of iota- and
kappa-carrageenan is Kappaphycus and Eucheuma gen-
era, while the lambda carrageenan is mostly extracted
from sporophytes of several marine algae belonging
to the family Gigantinaceae. Recently, a new type of
carrageenan (kappa2-carrageenan) has been marketed
by Shernberg Corporation (Cebu, Philippines), specially
developed for use as a binder and gelling agent.
Chemically, kappa2-carrageenan differs by being a
hybrid polysaccharide with kappa and iota units in the
same polymer chain (with a varying k/i ratio).55,56
Kappa- and iota-carrageenans can be gelified and the
former results in relatively hard and brittle gels, while
the iota ones are flexible and soft. Properties of the gel
can be controlled by the concentration of polysacchar-
ides, mixture with other polysaccharides and by com-
plexation with different alkali metal ions.57 All types of
carrageenan are soluble in water, but at low tempera-
tures, only lambda form is soluble and hence hardly
forms gels.
Carrageenan is extracted from red algae by solubilisa-
tion in hot mild alkaline solutions.58 This process is
simultaneously an extraction and a modification step,
because the precursor biosynthetic molecules are con-
verted to its mature form enhancing the gelling properties
of the final product,59 the abovementioned kappa, iota
and lambda forms. Several purification strategies are
already described in the literature and even commercially
available, comprising dialysis, previous extraction of
other components, reprecipitation, among others. The
resulting polysaccharide is being currently used in new
biotechnological approaches, taking advantage of its high
potential for chemical modification60 and interesting
viscoelastic61 and biological properties.62,63
Chitin and chitosan
Chitin, the second most abundant natural polymer, just
after cellulose,64,65 is part of the organic matrix of
exoskeletons of arthropods such as crustaceans (e.g.
crabs, lobsters and shrimps) and of endoskeleton of
mollusks.64–66 Chitin can be also found as a major
polymeric constituent of the cell wall of fungi and algae,
with fungal chitin presenting a greater uniformity in com-
position when compared with animal chitin. However,
chitin in fungi is associated with other polysaccharides, as
e.g. cellulose, glucan, mannan and polygalactosamine
which make its isolation difficult.64
Structurally, chitin is composed by a linear chain of
(1R4) linked 2-acetamide-2-deoxy-b-D-glucopyranose
units,65 also designated as N-acetyl-D-glucosamine
units. In its extracted crude form, chitin has a highly
ordered crystalline structure with strong inter- and
intramolecular hydrogen bonds, which chain arrange-
ment leads to two allomorphs: a and b.66 a-chitin is by
far the most abundant, being present in arthropods, and
is characterised by an antiparallel arrangement of the
chains, which leads to stronger intra- and intermolecular
hydrogen bonds.
The rare b-chitin, found in association with proteins
in squid pens, is characterised by a parallel chain
arrangement, and the weaker intermolecular hydrogen
bonds render a materials with higher reactivity and
higher affinity towards solvents.64 These forms can be
differentiated by infrared and solid-state nuclear
7 Structural schemes of k (kappa), i (iota) and l (lambda) carrageenan
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magnetic resonance spectroscopy together with X-ray
diffraction.19,64
Despite its huge availability, the utilisation of chitin
has been restricted by its poor solubility in usual organic
solvents.64,65 In fact, only few examples of solubilisation
of chitin are known, such as hexafluroacetone and N,N-
dimethylacetamide containing 5–8% lithium chloride,
which have been used to prepare chitin-based structures
from chitin solutions.67,68 Recently, room temperature
ionic liquids, like 1-butyl-3-methylimidazolium acetate,
have been proposed as new solvents for derivatisation of
native chitin using green chemistry principles.69
In this sense, most attention has been devoted to the
deacetylated derivative of chitin, chitosan. Chitosan is
composed of D-glucosamine (70–90%) and N-acetyl-D-
glucosamine (10–30%) units, connected through by b
(1R4) glycosidic linkage.65 In fact, the structural
difference between chitin and chitosan is determined
by the deacetylation degree, i.e. the ratio of deacetylated
units in the polymer chain, since the structural scheme,
in Fig. 8, is identical for both polymers.
Some authors point a value of degree of deacetylation
varying from 50% to 90% for chitosan,70 but the most
commonly accepted idea is that chitosan is the derivative
which is soluble in dilute acetic acid solutions.
Both the content and the sequence of these units will
determine the physico-chemical and biological proper-
ties of chitosan65,71 together with its molecular weight,65
which may range from 50 to 1000 kDa,72 depending on
the source and manufacturing procedure. Chitosan has
many attractive properties, such as its polyelectrolyte
and cationic nature, mucoadhesion, haemostatic action,
biodegradability, bacteriostatic and fungistatic activity,
and presence of reactive functional groups.64,65,71
Because of the stable crystalline structure, chitosan is
normally insoluble in water, but soluble in dilute
aqueous acidic solutions below its pKa y6?3, in which
amine (2NH2) groups in glucosamine units are con-
verted into the soluble protonated form ({NHz3 ).
71,73
This pH-dependent solubility of chitosan provides a
convenient mechanism for processing it under mild
conditions, e.g. diluted solutions can be used in the
production of membranes,74,75 while viscous solutions
can be gelled in high pH solutions or baths of non-
solvents such as methanol or sodium hydroxide to form
particles76 or fibres.77 Alternatively, porous structures
and tubes have been obtained by freezing and lyophi-
lisation of chitosan solutions and gels where their mean
pore size can be controlled by varying the freezing
temperature/rate and pore orientation controlled by
thermal gradients.73,78 Besides that, its high charge
density (positive electrical charge) in solution allows
chitosan to form insoluble ionic complexes or complex
coacervates with a wide variety of water-soluble anionic
polymers.78,79 Also, the cationic nature of chitosan is
primarily responsible for electrostatic interactions
with anionic GAG, proteoglycans and other negatively
charged molecules. Additionally, chitin and chitosan
have been investigated as an antimicrobial material
against a wide range of target organisms like algae,
bacteria, yeasts and fungi using chitosan in different
forms (solutions, films and composites).80–82 Although
the exact mechanism for its antibacterial action is not
fully understood, the molecular weight and the degree
of acetylation are important factors that may con-
tribute for such activity.82 Other studies also indicated
that in contact with blood, chitosan activates the for-
mation of clots as a result of the interaction of the
amino groups with the acid groups of blood cells.83 For
that, it is claimed as good haemostatic agent, being
used as biodegradable sponges and bandages.66 Never-
theless, other investigations indicated that chitosan has
a natural selectivity for heavy metal ions, and is useful
for treatment of wastewater.84 Furthermore, the pre-
sence of amino groups has been beneficial for chemical
modifications on chitin/chitosan to construct a broad
range of useful derivatives with satisfactory mechan-
ical, solubility and biological properties for specific
purposes.18,66,85
Commercially, chitosan is almost all obtained from
chitin previously isolated from crustacean exoskele-
tons.19 Basically, the chitin isolation from those sources
consists of three important steps: demineralisation (acid
removal of calcium carbonate), deproteinisation (re-
moval of proteins) and depigmentation (removal of
pigments), which involve the use of hydrochloric acid
baths such as 2?5% HCl solution,86 alkaline treatment
using typically 2% NaOH solutions86 and a solid–liquid
extraction with acetone or other solvents or a mild
oxidising treatment respectively64,87,88 in a 1 : 20 solids to
solution ratio.86 Depending on the severity of these
treatments, such as temperature, reaction time, concen-
tration of the chemicals, concentration and size of the
crushed shells, the physico-chemical characteristics of
the extracted chitin will vary.66 Then, chitosan is ob-
tained from chitin by a deacetylation reaction. Accord-
ing to literature,87,89,90 two methods are used for dea-
cetylation of chitin: the Broussignac process and Kurita
process. According to Broussignac,91 a mixture of solid
potassium hydroxide (50% w/w), 96% ethanol (25% w/w)
and monoethylene glycol (25% w/w), which is nearly an
anhydrous reaction medium, is used as deacetylation
reagent. In Kurita process,92 a suspension of chitin in
aqueous sodium hydroxide solution (50% w/v) is heated
up to a certain temperature, under a nitrogen stream
with stirring. In both processes, after the desired
reaction time, the solid is filtered off and washed with
distilled water to neutral pH. It can be further dried
with ethanol, acetone or in an oven at 50uC or below.
Figure 9 summarises the sequential steps for the just
described isolation of chitin and further conversion into
chitosan. Derivative processes using different reaction
conditions (reaction time, temperature, concentration
and nature of alkaline reagent) and multiple repeating
steps can be also found in literature. The Broussignac
8 Structural scheme of chitin and chitosan exhibiting N-
acetylglucosamine (on the left) and glucosamine (on
the right) units, with m smaller than n for chitosan
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process presents the advantage to provide chitosan with
better quality (higher molecular weight and higher degree
of deacetylation) and can be used with stainless steel
reactors (industrially relevant), while the Kurita process
does not allow reaching a very high deacetylation without
larger reaction time and higher temperature and thus
larger degradation of polysaccharide chain.87
Others
The oceans continue to provide new opportunities for
the discovery of valuable materials from different
organisms, with polysaccharides receiving the most
interest (Table 3). These compounds encompass a wide
variety of chemical structures and functionalities, broad-
ening their applicative potential. In fact, applications of
novel marine molecules are found in foods, cosmetics,
pet food, animal feeds, dietary supplements, bioactive
packaging and industrial products, as well as in bio-
medical high-tech fields.
Among the wide variability of marine origin mole-
cules, algae sulphated polysaccharides are of proven
economical importance, demonstrated by their wide
application in food industry and medicine and because
they found no equivalent in terrestrial organisms.
There are four major classes of algae, namely,
Rhodophyta (red), Phaeophyta (brown), Cyanophyta
(blue-green) and Chlorophyta (green). From these, red
and brown algae are the most explored and the main
sources of economically and industrially relevant poly-
saccharides, specifically the abovementioned agar, carra-
geenan and alginate.93 However, as the main constituents
of seaweeds are polysaccharides, many others can be
obtained from algae with interesting properties that
justify any efforts in their study and applicative develop-
ment. Besides, other polysaccharides can be also obtained
from different marine sources, such as animal or
bacterial. In this perspective, it is here highlighted the
considerable attention that is being given to fucoidan or
ulvan, two sulphated polysaccharides that can be found
in brown and green algae respectively.94,95 In addition,
other non-common polysaccharides are also being con-
sidered, such as tunicin, which is an highly crystalline
marine-derived cellulose of animal origin extracted from
tunicates,96 laminarin, which is a linear storage glucan
that can be extracted from some species of brown algae 97
and furcellaran, which is an anionic sulphated polysac-
charide extracted from the red alga and that may also be
considered a type of k-carrageenan.98
9 Scheme of common process for isolation of chitin from raw materials such as crustacean shells and squid pens
(dashed arrows) and its further conversion into chitosan
Table 3 Principal marine organisms groups and their related polysaccharides
Marine source Examples of polysaccharides
Algal Starch, laminarin, cellulose, mannans, glucomannans, xylans, pectic acid, complex
hemicelluloses, carrageenans, furcellaran, agar, glycogen, glucans, lipopolysaccharides
Microbial Different extracellular polymeric substances (EPS)
Fungi Capsular polysaccharides and different EPS
Others Tunicin, chitin, chondroitin sulphate
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Glycosaminoglycans
Glycosaminoglycans (GAGs) are linear, complex and
polydisperse natural polysaccharides, typically bearing a
repeating disaccharide unit constituted by a hexose and
a hexosamine. The presence of sulphated GAG in a
diverse range of marine phyla-like sponges (Porifera)99
and several classes of fishes (Actinopterygii and others),
particularly in commercially relevant species like sharks,
skate, codfish, salmon and trout,100–102 is now well
documented and increasing interest is being shown by
different sectors (research, biochemical industries, bio-
phamaceutical, nutraceutical and biomedical). Because
of their unusual chemistry, marine-derived GAGs are
being extensively studied because of their pharmaceu-
tical activities (anti-pathogenic, antitumor and antic-
oagulant) and as new biomaterials with application in
different areas (such as biomedical/bioengineered bio-
material applications, i.e. bioadhesive molecules, tissue
engineering and regenerative medicine research). How-
ever, heterogeneity on GAG can be observed when
comparing different species, intra-species and even
within the same organism comparing different maturing
states and tissues,103 because of their high susceptibility
for post-translational modification by several enzymes –
like glycotransferases, thus representing a main obstacle
when considering these biopolymers for the develop-
ment of different applications.104
Different types of glucosaminoglycans attached to
different protein cores compose the proteoglycans,
which hold important properties in cells, connective
tissues and basal membranes, due to the structure and
charge of their polyanionic GAG side chains. They are a
highly heterogeneous group that can be responsible for
properties like increased hydration or capacity to bind
and store specific growth factors,105–108 and have the
potential to act as co-receptors in cellular adhesion as
well as to interact with extracellular matrix molecules,
such as laminin and fibronectin.109 The heterogeneity
that can be found in sulphate composition can result in
large differences in negative charge density, which is
directly associated with protein binding 106,110 and play a
role in cell adhesion and proliferation mechanisms.111
GAG can be isolated from selected proteoglycan
bearing tissues following quite general methods.112–118
Intact proteoglycans generally require the use of
dissociative solvent conditions for efficient extraction
from the tissue,112 with high guanidine HCl concentra-
tions (ordinarily at 4M) being widely employed. The use
of protease inhibitors is highly recommended to hinder
early proteoglycan degradation. The concomitant use of
detergents is also needed, in particular non-ionic
detergents (such as Triton X-100 and NP-40 with low
critical micellar concentration) or zwitterionic detergents
(such as 3-[(3-cholamidopropyl)-dimethylammonio]-1-
propanesulfonate, with high critical micellar concentra-
tion). Following proteoglycan extraction, the use of
specific enzymes (like keratanase, chondroitinase ABC
and hyaluronidase) to break GAG linkage with protein
core is required (so the isolation of specific GAG is
achieved).119 After the separation from the protein core,
different separation methodologies can be applied,
including sodium dodecyl sulfate–polyacrylamide gel
electrophoresis), membrane separation and chromato-
graphic separation (e.g. size exclusion chromatography).
Further purification can be achieved with gel filtration,
dialysis and ultrafiltration.
Because of their exceptional diversity in molecular
constructions and interactions, there is no single set of
extraction or separation procedure usable for every
proteoglycan and every source. Thus, these general
principles have to be modified in different combinations
for successful isolation of a particular GAG of interest.
This review will give emphasis to chondroitin sulphate
(CS), dermatan sulphate (DS), heparan sulphate (HS)
and keratan sulphate (KS), as well as to the non-sulfated
GAG hyaluronan.
Chondroitin sulphate
Chondroitin sulphate (CS), has been isolated from various
natural sources including terrestrial species (bovine,
porcine and chicken cartilage) and marine species.120–122
Regarding marine sources, it has been obtained from
whale,123 shark,124,125 skate,119 squid,126,127 salmon,128
king crab129 and sea cucumber.130 Presence in marine
invertebrates, such as Cnidaria, Polychaeta and molluscs,
has also been described.131 Among them, shark cartilage
has been the most commonly used as a commercial source
of non-mammalian CS. Still, obtaining CS from shark
cartilage might become problematic in the future, as the
price of this raw material has been rising and ecological
aspects are the reasons why it is expected to have new
developments in the upcoming years.102
CS consists in a disaccharide basic unit of hexosamine
(D-galactosamine) and hexuronic acid (D-glucuronic
acid) that are arranged in alternating unbranched
sequence that can bear sulphate ester substituents in
a variety of positions. Depending on the species, there
are variations in molecular weight, chain length and
the position of sulphate substitution, which renders
sequence heterogeneity. Nevertheless, the most com-
mon (and commercial) form of CS presents sulphated
groups at position C-4 or C-6 of the hexosamine in the
disaccharide basic unit (corresponding to chondroitin-
4-sulphate and chondroitin-6-sulphate respectively).132
Figure 10 illustrated the chemical structure of this
disaccharide basic unit. In particular, marine CS
contains oversulphated disaccharides, including 2,6-
(CS D, shark cartilage), 4,6-(CS E, squid and salmon
cartilage) and 3,4-(CS K, king crab) disulphated
hexosamine.133–135
CS and DS (discussed in the next section) chains have
intriguing functions in central nervous system develop-
ment, wound repair, infection, growth factor signalling,
10 Structural scheme of glucuronic acid and sulphated
hexosamine, the disaccharide repeating unit of chon-
droitin sulphate
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morphogenesis and cell division, in addition to their
conventional structural roles.136
The CS enclosed in a variety of tissues can be
extracted along with other GAG by proteolytic diges-
tion. Once extracted, CS can be purified from other
contaminant GAG by precipitation with organic sol-
vents or enzymatic degradation of contaminant GAG
species or also by column chromatography techniques.
The most frequently assays for tracking CS isolation
typically utilise uronic acid content as a marker.132
Recovery and purification with concomitant detection of
CS can be performed by three main methodologies: (1)
precipitation with ethanol; (2) precipitation with qua-
ternary ammonium compounds;137 and (3) ion-exchange
chromatography.132 The colorimetric carbazole–sulfuric
acid assay, based on the reaction of unstable acid
hydrolyzed dehydrated derivatives of hexuronic acid
with carbazole, is frequently used to quantify the GAG
content in solution. Alternatively, there are colorimetric
assays, such as alcian blue, or 1,9-dimethylmethylene
blue,138 although they are not so specific. Electro-
phoresis is then generally utilised for qualitative and
quantitative analyses of GAGs in mixtures or single
species, in particular using cellulose acetate,139 poly-
acrylamide gel140 and agarose gel.103,141,142 If necessary,
enzyme digestion may be explored to remove contami-
nant nucleic acids.141
Dermatan sulphate
From marine environment, Ben Mansour et al.143,144
described the isolation and characterisation at a
molecular level and also biological properties of
dermatan sulphate (DS) from ray skin (Raja radula).
Similar studies were performed by Volpi et al.145 using
the marine clam Scapharca inaequivalvis and Pelli
et al.146 with DS present in the integument of the
anuran (amphibian) Bufo ictericus.
DS, also known as chondroitin sulphate B, is
composed of linear polysaccharides assembled as
disaccharide basic units containing a hexosamine, N-
acetyl galactosamine (GalNAc) or glucuronic acid
(GlcA) joined by b-1,4 or -1,3 linkages respectively.
DS is defined as a chondroitin sulphate by the presence
of GalNAc. The presence of iduronic acid (IdoA) in DS
distinguishes it from chondroitin sulfphates-A (4-O-
sulphated) and -C (6-O-sulphated) and relates it to
heparin and heparin sulphate (discussed later on), which
also contain this residue.
DS serve as key biological response modifier by acting
as: (1) stabiliser, cofactor and/or co-receptor for growth
factors, cytokines and chemokines; (2) regulator of
enzyme activity; (3) signalling molecules in response to
cellular damage, such as wounding, infection, and
tumorigenesis; and (4) target for bacterial, viral and
parasitic virulence factors for attachment, invasion and
immune system evasion.136,147
Owing to the chemical similarities of DS and CS, as
observed by comparing their chemical structures illu-
strated in Figs. 11 and 10 respectively, very similar
methodologies can be used for their isolation and
purification from tissues136,139,148 and thus a similar
process to the one describe for CS can be used for DS,
choosing the appropriate raw materials.
Heparan sulphate
Heparan sulphate (HS) is also a member of the GAG
family of carbohydrates and is related in structure to
heparin.149–151 Nevertheless, the criteria for distinguish-
ing between heparan sulphate and heparin are still
dubious. The term heparan sulphate has been tradition-
ally used to describe heparin-like byproducts of the
industrial preparation of heparin from animal tissues
such as bovine lung or pig mucosa. The heparan
sulphates in these byproducts had little or no antic-
oagulant activity and displayed considerable heteroge-
neity in molecular mass and sulphate content with
degree of polymer sulphation. However, it is now clear
that HS has a distinct structure from heparin and a
broader range of biological activities. In contrast to
heparin, which is only synthesised by connective tissue
mast cells, HS in the form of proteoglycans are found
on cell surfaces or in the extracellular matrix of all
mammalian organs and tissues. Both consist of a
variably sulfated repeating disaccharide unit and the
only GAG in which N-sulpho-glucosamine monosac-
charide (GlcNSO{3 ) is present. The initial product in
their biosynthesis is a non-sulphated polymer composed
of alternating sequences of glucuronic acid (GlcUA)
and N-acetylglucosamine (GlcNAc). This precursor
substance is then enzymatically transformed into com-
plex sulphated derivatives.
HS polysaccharide is composed of alternating hexuro-
nic acid [D-glucuronic acid (GlcA) or L-iduronic acid
(IdoA)] and D-glucosamine (GlcN) residues, which may
be N-sulphated (NSO) or N-acetylated (NAc). An
example of the chemical structure of a possible repeating
unit of a heparin sulphate is given in Fig. 12. On the other
hand, heparin is composed by IdoA(2S)–GlcNS(6S).
Problems arise when defining hybrid GAGs that contain
11 Structural scheme of dermatan sulphate repeating unit
(Akane700 user, Wikimedia Commons 2011)
12 Structural scheme of heparan sulphate repeating unit
(Hsa2011 user, Wikimedia Commons 2011)
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both ‘heparin-like’ and ‘HS-like’ structures. It has been
suggested that a GAG should qualify as heparin only if its
content of N-sulphate groups largely exceeds that of N-
acetyl groups and the concentration of O-sulphate groups
exceeds those of N-sulphate.
A comprehensive survey of different classes of in-
vertebrates has shown that HS-like and/or heparin-like
compounds, besides CS, are present in many species.
There is a significant number of works describing HS-/
heparin-like compounds from a wide number of marine
sources, from molluscs – Tapes phylippinarum,152 crusta-
cean Penaeus brasiliensis,103,153 and from invertebrates154
and Algal heparinoids.155
In fact, HS is found in all animal tissues and it occurs
as a proteoglycan in which two or three HS chains are
attached in close proximity to cell surface or extra-
cellular matrix proteins.156 Under physiological con-
ditions, the ester and amide sulphate groups are
deprotonated and attract positively charged counter-
ions to form a salt and is in this form that is thought to
exist at the cell surface.157 In this way, HS binds to a
variety of protein ligands and regulates a wide variety
of biological activities, including developmental pro-
cesses, angiogenesis, blood coagulation and tumour
metastasis.158
Keratan sulphate
The extracellular matrix of lophophores from some
brachiopods (Brachiopoda phylum, order Terebra-
tulida) stains for both collagen and acidic GAG, being
intensely stained in a certain region with antibodies
against keratan sulphate (KS).131 The presence of KS
was also described in teleost fish (catfish – Corydoras
aeneus – and loaches – Acanthophthalmus semicinctus,
Botia horae159), in particular in skin, bounded to the
protein core via an N-glycosyl linkage between N-acetyl-
D-glucosamine and asparagines.160
KS is an atypical GAG specimen and represents the
only of this family in which there is no acidic residue
alternating in the basic unit structure with an N-
acetylated amino-sugar. The basic unit of the KS is a
repeating disaccharide of N-acetylated lactosamine [-3
galactose b1–4 N-acetylglucosamine b1-], which is
partially substituted in C6 with O-ester sulphate groups
of one or both monosaccharide residues. Figure 13
illustrates the chemical structure of the disaccharide
repeating unit with the N-acetylglucosamine unit bear-
ing the sulphate group in C6. The extent of N-
acetylglucosamine sulphation is normally complete
contrasting with galactose (that can be quite varied),
relating to the origin of the KS.
Three distinct KS families are now documented,
classified according to the nature of the link section to
the protein core.161 KS-I systems include those derived
from cornea and from the small cartilage proteoglycan,
fibromodulin.162 This type is N-linked to an asparagine
residue within the protein core; through an N-acetylglu-
cosamine extending from the central residue of a triple
mannose unit. KS-II linkage is typical of the skeletal KS
found in articular and non-articular cartilage, nasal
septa and tracheal rings. The N-acetylgalactosamine
anomerically attached through an O-link to either a
serine or a threonine contained in the core protein. It
was first recognised in material isolated from the nucleus
pulposus of intervertebral discs and costal cartilage. A
third class (KS-III) has been proposed and it was first
isolated from brain tissue163,164 in which the chains are
again attached to a protein core through an O-glycosidic
linkage, which in this case connects a mannose residue
contained in a GlcNAc(b1–3)Man-sequence to either
serine or threonine.165
Pfeiler166 described and compared several methods to
isolate the proteoglycans fractions bearing KS. Extrac-
tion of proteoglycans was executed under both dis-
sociative (generally described above) and associative
(performed as described above except that 4M guanidine
HCI was deleted from the homogenising solution and
extracted proteoglycans were dissolved in water only
conditions). Free KS chains are obtained by both an
enzymatic method utilising chondroitinase ABC and by
ethanol fractionation. The purity of the preparation is
checked by cellulose acetate electrophoresis.166 Pre-
parative and purification methods to obtain medical
grade materials can be also further explored.166
Hyaluronic acid
Hyaluronic acid (HA), or hyaluronan, a naturally
occurring non-sulfated glycosaminoglycan, is a major
macromolecular component of the intercellular matrix
of most connective tissues such as cartilage, vitreous of
the human eye, umbilical cord and synovial fluid,167
being also found in umbilical cord and rooster comb.
HA can be also found in marine environment, mostly
in cartilaginous fishes and in vitreous humour of
different fish species. In addition, HA can be easily
and controllably produced in large scales through
microbial fermentation, from strains of bacteria such
as Streptococci,167 enabling the scale-up of derived
products and avoiding the risk of animal-derived
pathogens.
HA consists of alternating disaccharide units of a-1,4-
D-glucuronic acid and b-1,3-N-acetyl-D-glucosamine,
linked by b (1R3) bonds.168 Figure 14 illustrates the
chemical structure of this disaccharide repeating unit.
Initially, it was thought that the major role of HA was
to serve as an inert molecular filling of the connective
tissue.169 However, despite their uniform and simple
primary structure, HA polymers have extraordinarily
wide-ranging and often opposing biological functions
depending on the size of the molecule.167,169 Large
matrix polymers of HA, which can reach molecular mass
values as high as 107 Da and are thus associated to
unique viscoelastic and rheological properties, are space-
filling, antiangiogenic and immunosuppressive materi-
als. Intermediate-sized polymers comprising 25–50
13 Structural scheme of a keratan sulphate repeating
unit, with only one sulphate group in C6 of N-acetyl-
glucosamine residue (galactose unit can be also
sulphated in C6)
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disaccharides are inflammatory, immunostimulatory
and highly angiogenic, whereas smaller oligosaccharides
are antiapoptotic and induce heat shock proteins.170
In cartilage, despite its relatively low content, HA
functions as an important structural element of the
matrix, forming an aggregation centre for aggrecan, a
large chondroitin sulfate proteoglycan that retains its
macromolecular assembly in the matrix due to specific
HA–protein interactions.171 These aggregates have
enormous molecular mass of up to 100 MDa and
are embedded within a collagenous framework.172 In
synovial fluid, the high concentration of high molar
mass HA provides necessary lubrication for the joint
and serves as shock absorber, due to its enhanced
viscoelastic properties,173 reducing friction of the mov-
ing bones and diminishing wear of the joint. Under
inflammatory conditions of arthritic diseases, such as
osteoarthritis or rheumatoid arthritis, high molar mass
HA is degraded by reactive oxygen species, which
reduces its viscosity and impairs its lubricant and shock
absorbing properties leading to deteriorated joint move-
ment and pain.174 In the skin, the largest organ of the
human body, constituting the primary protecting barrier
between the underlying tissues and the hostile action of
the environment, HA plays a role of a scavenger of free
radicals generated by the ultraviolet rays from sunlight,
which otherwise would inflict oxidative stress on cells,
which might damage their genetic material, thus causing
degeneration and death.175
Besides recombinant technology, commercially avail-
able hyaluronan can be produced by extraction from
umbilical cord, rooster comb, synovial fluid or vitreous
humour. The first industrial process, schematised in
Fig. 15, was described by Balazs176 and consists in
freezing of umbilical cords and rooster combs, in order
to destroy the cell membranes, followed by extraction of
HA with water, which was then precipitated with
ethanol, chloroform or other organic solvents. The
resulting product needs to be further purified and a yield
of 0?09% (0?9 g of HA per kilogram of raw material)
was observed.
Collagen
Collagen is structurally formed as a triple helix by three
extended protein chains that wrap around one another.
Collagen and gelatin are different forms of the same
macromolecule and gelatin is the partially hydrolysed
form of collagen. Heat denaturation easily converts
collagen into gelatin. Collagen and gelatin are unique
proteins compared to muscle proteins and this unique-
ness relies on its amino acid content, in particular non-
polar amino acids such as Glycine – Gly (30%), Alanine
– Ala (10%) and Proline – Pro (10%), and to the
significant presence of Hydroxyproline – Hyp.177–179
Figure 16 shows a cartoon of one of the protein chains
in the collagen triple helix bearing the typical Gly, Pro
and Hyp residues. Although main industrial sources of
collagen and gelatin are bovine and porcine skin, many
studies have been conducted to extract collagen and
gelatin from marine sources and have used to screen
their potential industrial applications.177,178,180–182 These
efforts and the expected interest of the industry are
explained by the comparative unpopularity of porcine
skin collagen and gelatin in relation due to religious
14 Structural scheme of hyaluronic acid disaccharide
repeating unit
15 Scheme of extraction of hyaluronic acid from raw
materials such as rooster combs and umbilical cords,
according to the procedure described by Balazs176
16 Cartoon of one protein chain from collagen triple
helix, with the typical amino acid residues of Glycine,
Proline and Hydroxyproline (Joint-Muscle-Relief.com,
November 2011)
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constrains and to active discussion on the use of bovine-
derived collagen and gelatin due to the mad cow disease,
bovine spongiform encephalopathy and the risk they
pose to humans. In contrast, fish collagen and gelatin
have a relatively low risk of possessing unknown patho-
gens such as bovine spongiform encephalopathy.183,184
In marine environment, collagen can also be found in
several marine sponges (e.g. Chondrosia reniformis),180
showing unique advantages compared to mammalian
connective tissue-extracted collagens,185 as well as from
gellyfish.186–188
Techniques have been developed to obtain collagen-
based macromolecules with different physico-chemical
properties, such as very long and compact fibres, films,
nano- and microparticles or porous scaffolds for
biomimetically inspired hybrid materials or for biocom-
posite such as the newly-discovered silica–aragonite–
chitin biocomposites189 in demosponges. These may
serve for example as models for biomimetic synthesis of
composites analogous to well established chitosan–silica
hybrid materials, with very attractive bioactive proper-
ties for applications in biomedicine or as biocompatible
structures that would support and organise functional
tissues if applied in tissue engineering. Nevertheless,
collagen can be obtained from several marine resources,
such as fish skins, following simple procedures,177,190,191
according to which fish skins are cleaned and further
treated with acetic acid solution (normally 0?5M) for
collagen extraction, sometimes with concomitant use of
10% pepsin. When considering marine sponges, the
available methodologies are different, since sponge
collagen is not soluble in acetic acid solution. Thus,
Swatschek and co-workers proposed an extraction
methodology aiming scale-up, based on treatment with
100 mM Tris-HCl buffer (pH 9, 10 mM EDTA, 8M
Urea, 100 mM 2-mercaptoethanol), during 24 h, with
stirring, at room temperature, after which the extract is
centrifuged and collagen is precipitated from the super-
natant by adjusting the pH to 4 with acetic acid.180
Recombinant collagen will be an alternative solution
for large scale collagen production. Up to date, there is a
great diversity in systems allowing the production of
recombinant proteins ranging from the simplest (bac-
teria) to more sophisticate ones (as transgenic organ-
isms), all being used for the production of collagen
molecules or derived domains. However, the same
principle governs them all: the cDNA of interest is
sub-cloned into an appropriate expression vector for the
expression of the protein in a cultured cell.192 Although
the Escherichia coli expression system combines several
advantages, its weaknesses for expressing eucaryotic
proteins lies in its being restricted to the production of
small fragments and the proteins produced lack post-
translational modifications. Thus, different eukaryotic
systems have been developed to try to achieve a higher
degree of similarity with the tissue proteins. Among
them, yeast (Pichia pastoris), insect cells (High Five, Sf-
9, S2) mammalian cells (HT1080, 293-HEK, CHO,
HeLa, COS-1) and tobacco cells have been used for
collagen production.192 The methylotrophic yeast Pichia
pastoris, in particular, is a favoured yeast species as
a host for heterologous protein production.193–197 P.
pastoris has the potential for high expression levels,
efficient secretion of target proteins, post-translational
modifications, and is easily grown to high cell densities
on mineral salt medium in bioreactors. It has been
demonstrated that P. pastoris is an efficient production
system also for very large and complex proteins, such as
collagens, which besides the recombinant gene(s) needed
for the collagen polypeptide chain(s), needs the parallel
expression of two different genes coding for collagen
prolyl 4-hydroxylase (C-P4H), an enzyme required for
the thermal stability of collagens.198–200
Ceramics
Besides biopolymers, natural materials of marine origin
such as corals, nacres and sponges provide also an
abundant source of inorganic materials with significant
relevance for tissue replacement and regeneration. Much
work has been treated extensively in the literature,
though data on their properties, sources, as well as
isolation, chemical modification and purification meth-
ods are still scarce. This section will review the advances
on marine-derived calcium compounds (carbonates and
phosphates) and silicates with relevance for biomedical
applications.
Calcium carbonates and phosphates
Calcium phosphorous compounds such as hydroxyapa-
tite (HAp), Ca10(PO4)6(OH)2, have a special importance
in the biomedical field due to its similarities with the
mineral constituents of bones. By its turn, the abundant
calcium carbonate (CaCO3), which is not as interesting
as calcium phosphates from the biomedical application
point of view, can be the precursor material for ob-
taining different calcium phosphates and consequently,
there is a growing interest in finding new sources of this
inorganic material.
Calcium carbonate (aragonite or calcite forms) can
be found in many marine organisms. Several good
reviews201–203 give special attention to these materials,
not only summarising the aspects dealing with the
evolution and physiology of those organisms but also
looking into other properties such as inorganic/organic
composition and mechanical properties. Some examples
of marine species possessing calcium carbonates that
might be used as calcium precursors, and thus further
exploited in the biomedical field,204–210 can be found in
Table 4.
Although there are many sources of calcium carbo-
nate, coral skeletal carbonate has been attracting great
deal of attention namely as substitute materials for
orthopaedics and dentistry. Corals possess a unique
architecture, namely, porosity, pore size and pore
interconnectivity.211 Actually, these characteristics have
been shown212 to be important in bone tissue regenera-
tion. Besides microstructure, other characteristics play a
key role in the in vivo performance of these biomaterials,
such as microstructural composition and mechanical
properties. In this respect, it has been reported213 that
marine-derived calcium carbonate skeletons are unsui-
table for most applications aiming bone tissue repair due
to its fast dissolution rate and poor structural stability.
Actually, Braye et al.214 investigated the resorption rate
of different bone substitutes when implanted in femora.
This study has confirmed that the kinetics of coral
resorption was faster than that of HAp. To circumvent
these limitations, several authors215,216 have shown the
possibility of converting the hard calcium carbonate
skeleton of mineralised algae into more stable structures
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such as calcium phosphates. These coral-derived materi-
als have been mainly used in the forms of granules and
blocks for bone grafting and in bone tissue engineering
scaffolding.204,217–219 However, while they succeeded in
generating the marine-derived calcium phosphates, often
the original coral architecture was lost upon the
conversion process.
In the work reported by Oliveira et al.,220 different
routes to convert the calcium carbonate skeleton of
Coralline officinallis red algae (Fig. 17a and b) into
calcium phosphates are described. This interesting work
showed that by performing a combined treatment
(thermal and chemical), it became possible to obtain a
calcium phosphate material with HAp nanocrystallites,
while the native microstructure of the red algae could be
maintained. First, red algae particulates (Figure 17c)
free of the organic phase were obtained by heat
treatment at 400uC for 3 h in a furnace. This tempera-
ture was chosen since it has been reported221 that at
higher temperatures, carbonate phases can decompose.
Then, the conversion of the calcium carbonate skeleton
into calcium phosphates (Ca–Ps) was achieved following
the hydrothermal exchange (equation (1)) strategy222
10CaCO3z6(NH4)2HPO4z2H2ORCa10(PO4)6
(OH)2z6(NH4)2CO3z4H3CO3 (1)
This step forward seems very promising towards
developing adequate algae-derived calcium phosphate
particulates (Figure 17d) to find applications as bone
filler and scaffolds for tissue engineering strategies.
Interestingly, Walsh et al.223 prepared equivalent
coralline-derived HAp by developing a low-pressure
hydrothermal process. The synthesis method consisted
in using ambient pressure at a low temperature of 100uC
in a highly alkaline environment to convert the original
calcium carbonate structure of coralline into a calcium
phosphate material. Results have shown that the resulting
HAp maintained the unique microporous structure of the
original algae, as evidenced in Fig. 18. Therefore, in order
to convert carbonate phases into HAp using the hydro-
thermal method, we should bear in mind: (1) to remove
the organic matter from algae by burning or using che-
mical methods; (2) to avoid decompose carbonate phases;
and (3) to preserve the original algae morphology.
Besides using calcium carbonates as precursors,
calcium phosphates, including hydroxyapatite, can be
17 Photos of Coralline officinallis red algae used as source of calcium carbonate: Coralline officinallis (a), SEM image
of Coralline officinallis (b), SEM image of Corallina after heat treatment at 400uC for 3 h (c) and SEM image after heat
treatment at 400uC for 3 h, followed by chemical treatment with ammonium phosphate dibasic (d)
Table 4 Marine organisms (invertebrates and vertebrates) possessing calcium carbonate with potential interest in the
biomedical ﬁeld
Sources Species Potential application(s) References
Corals Coralline officinallis Bone filler 204
Lithothamnion glaciale Bone filler 205
Phymatholithon calcareum Bone filler 205
Sponges Calcareus sponge spicules from triactines
of Pericharax heteroraphis
Precursor material for
bioceramic coatings
202
Mollusc shells Nacre from Haliotis (abalone); Mytilus galloprovincialis and
Ostrea edulis (oysters); and Pinctada maxima (bivalve)
Precursor material for
bioceramic coatings
206–209
Fish bones Prionace glauca (blue shark) Bone filler and precursor material
for bioceramic coatings
210
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found and obtained directly from marine resources,
namely, in fish bones. In addition to the process of pyro-
lysis to eliminate all the organic matter and save the inor-
ganic calcium phosphates, Pou and co-workers224–227
have described a laser-based process for the production
of calcium phosphates from fish bones in microparti-
culate form, in which a laser beam irradiates the surface
of fish bones with the necessary energy to result in the
ablation of material in particulate form that is collected
into a filter by a perpendicular gas flow or stay dis-
persed in deionised water, where the procedure can be
performed.224,226 Figure 19 depicts a cartoon of this
laser ablation methodology (Fig. 19a), with an example
of calcium phosphate particles prepared by this
technique (Fig. 19b and c). Hydroxyapatite powder
can be reduced to obtain nanoparticles by using con-
tinuous wave as well as pulsed laser in deionised
water;224 following several mechanisms, such as melt
ejection and fracture225,227 and different crystal struc-
tures, can be obtained with experimental parameters
such as the energy of the laser and its pulse, where
pulsed laser promotes the formation of crystalline
nanoparticles, while the continuous wave laser favours
the formation of amorphous particles).226
Similarly to sea shells, different human body parts
(e.g. bone, tooth and mineralised tendon) are nanocom-
posites of protein and mineral which possess superior
mechanical properties.228 Succinctly, we can state that
from both mechanical and biological performance
perspectives, it is interesting to design man-made novel
materials for biomedical applications that mimic the
natural nanostructures consisting of protein and
mineral.
Biosilica
Biogenic silica, commonly known as biosilica, consists
of glassy amorphous silica and is formed in many
aquatic organisms (and in terrestrials as well, like higher
plants), such as sponges, diatoms, radiolarians and
choanoflagellates.229 The most representative biosilicify-
ing organisms are sponges and diatoms and those will be
the focus of this review.
18 SEM images of Corallina-derived hydroxyapatite after conversion process developed by Walsh et al. (reprinted from
Ref. 223 with permission from Elsevier)
19 a cartoon of the laser ablation process in deionised water for production of calcium phosphate particles, b HRTEM
image and c SEM image of calcium phosphate submicro- and microparticles respectively, obtained from ﬁsh bones
by using laser ablation technique (micrographs reprinted from Ref. 226, Open Access article distributed under the
terms of the Creative Commons Attribution License)
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Besides being inspiring and a valuable source of
marine collagen, as aforementioned, some sponges
species are also an important source of biosilica, as also
already mentioned. In fact, there are two classes of
sponges that have a silica skeleton: Demospongiae and
Hexactinellida; the third class, Calcarea, has a calcium
carbonate skeleton.229 Figure 1C shows one example of
a silica skeleton of a sponge from Hexactinellida class:
the impressive skeleton of Euplectella aspergillum
species,230 also known as glass sponge or Venus’ flower
basket. The silica skeleton is constituted by siliceous
spicules,231 which are rod-like glassy spikes consisting of
an axial filament surrounded by several hundred
concentric layers of hydrated silica.229 The process of
biosilica formation in sponges is enzyme-mediated. The
axial filament consists predominantly of an enzyme
called silicatein, with mediates the silicification process
around it through the formation of the mentioned
concentric layers.229,230,232–235 At a lower scale, these
layers are made of densely-packed silica nanoparticles in
the 70–200 nm range.229,236 The silica content of these
sponges can amount to 75% or more of the dry mass of
the animals. Collagen is also present, being the
predominant protein in the spicules, constituting thus
a composite material.229,234
If the objective is to isolate silica from these marine
sources, it can be accomplished for instance by treating
collected sponges with 5?25% (v/v) sodium hypochlorite
solution until all cellular material had been removed and
after washing with water, treating the residual material by
soaking in concentrated HNO3/H2SO4 (1 : 4) overnight.
The resultant acid-insoluble material consists of cleaned
silica spicules with an axial silicatein filament.236,237
Sponge spicules have been characterised in terms of
mechanical,230,238–240 optical241 and electric242 proper-
ties. These natural biocomposites have been charac-
terised as highly flexible and tough, which is attributed to
their layered structure and hydrated nature of sı´lica.238
Spicules present reduced stiffness240 and nanohardness238
as compared to commercial glass systems, but this bio-
genic silica has an architecture that provides a substantial
toughness238,240 and mechanical stability.230 It has been
also observed that sponge spicules can be excellent light
transmitters, functioning as single-mode, few-mode or
multimode fibres, with the lens-like structure at the end
of the fibre contributing to increase its light-collecting
efficiency.241 The refractive index of these biocomposites
is dependent on the organic material content, as well as
on hydration of silica.229 Regarding electric properties,
it was observed that sponge spicules are electrical
conductors, with the electric charge being probably
transported along the paths formed by collagen, since
deproteinised spicules presents a reduced electric
conductivity.242
In this perspective, sponge spicules are remarkable
structures that offer bioinspired lessons for potential
biomimetic design of several devices, such as optical
fibres, which could be fabricated at room temperature,
thus highlighting the advantages of the synthesis used by
biology.238,241 In the same way, the knowledge of sponge
enzymes silicatein and silicase is of great importance
also for nanobiotechnology, since they can be used on
the formation of nanocomposite materials, using na-
ture as a model for the production of new nanoscale
systems.237,243 This is particularly interesting because
enzyme-mediated silica formation allows the formation
of silica glass under mild conditions (low temperature,
low pressure and near-neutral pH), while the current
methods require high temperatures and pressures and
the use of harsh chemicals.229,234,237 On the other hand,
the work of Daniel Morse have been showing that this
knowledge can be also used for the production of other
materials using silicatein-mediated processes, such as
titanium, gallium and other metal(loid) oxides,237
including also semiconductors,244 but also polymer such
as polylactide.245 Moreover, it has been demonstrated
that equivalent processes can be used with native
silicatein, but also with recombinant forms237,245 or
even with bioinspired synthetic analogues.237,244,246
Diatoms are a major group of microalgae, being
normally unicellular organisms, although some form
chains or simple colonies. These are classified as centric
and pennate diatoms and can be distinguished from each
other on the basis of cellular symmetry, i.e. centric
diatoms are radially symmetrical, whereas pennate
diatoms are elongated and bilaterally symmetrical.229
Further details on the physiology of these organisms
may be found elsewhere.247
The living part of the diatom is within a box, which
is made up of silicon dioxide.248 These exoskeletons,
named frustules, are made of silica nanoparticles
assembled in a highly organised structure exhibiting
porous networks at different scales.249 Silica nanoparti-
cles are associated with a matrix of carbohydrates and
proteins, and thus frustules are in fact composite
materials and their nanostructure is species-specific
and genetically determined.229 Although the precise
mechanism of formation has not been clearly described,
it is known that the frustules are formed within a few
hours, from naturally-occurring precursors at low
concentrations.249 The mechanism of formation is
attributed to silica itself, through a complex inorganic
polymerisation process, in contrast with precipitation/
dissolution reactions described for carbonate and
phosphate minerals.249 Some authors argue that pH,
the presence of cations and salts and the concentration
of silica precursors play an important role in biosilici-
fication of diatoms.250 Other authors reinforce the
importance of silicic acid,251 key molecules called
silaffins252 and polyamines253 in silica formation in
diatoms.254
The siliceous exoskeletons remain intact when cells
die, rendering inorganic structures with morphological
features, which are of potential interest for industrial
applications.250 These silicified structures have two basic
types of macromorphologies, derived from the two types
of diatoms: one with bilateral symmetry and other with
radial symmetry (Fig. 20).
From these, there are an enormous variety of
micromorphologies, such as porous (with all types of
pore arrangements and morphologies), tubes and
ribbons, which exhibit high surface area being quite
interesting for the development of silica-based materials.
These micromorphology is reproduced with high preci-
sion within a given species since the process is genetically
encoded.253 However, in the oceans, after the cellular
death, the inorganic features sink to the ocean floor,
reappearing to the surface after millions of years of
aging as ‘diatomaceous earth’, which is much less in-
teresting for application purposes, since aging reactions
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contribute to the destruction of the attractive morphol-
ogies and moreover to the incorporation of contaminat-
ing minerals. Thus, when considering new applications
of biosilica, one should consider fresh diatomaceous
silica, harvested from the field or prepared from culture.
Moreover, fresh diatomaceous silica presents low con-
tamination with metals, such as Al or Fe, indicating that
diatoms synthesise a nearly pure silica matrix and thus,
for its further use, purification is not required.250
Besides the inherent interest of the morphology of
such silica features, it is also interesting to know and
understand the process of formation of such exoskele-
tons, since there may be a mimetic possibility of
controlling the formation and assembly of silica
nanoparticles in biological conditions, which can be
quite interesting for the design of nanodevices, such as
membranes and systems for controlled release or
bioencapsulation.249,255 In particular, the work that is
being developed by Kroeger, Sandhage and co-workers
is a good example of it, where the mechanism of biosilica
formation has been studied, in particular the role of
silaffins256–258 and that knowledge was further used for
the bioinspired synthesis of silica and titania materials,
including the co-assembly of other entities, such as
enzymes, which can be used on the design of new
biosensors.259–261 In fact, as in the abovementioned case
of sponge biosilica enzyme mediators, silicateins, this
biomimetic approach to the synthesis of silica and
titania materials can be pursued based on extracted
proteins and peptides, but also by using synthetic
peptide analogous.254
Biosilica is also being considered for biomedical
approaches, namely, for bone replacement and regen-
eration strategies. For instance, it has been observed
that human osteogenic sarcoma cells (SaOS-2) exhibited
an increased mineralisation activity when cultivated on
biosilica surfaces in the presence of b-glycerophosphate.
Moreover, concurrent coating of the substrate with
biosilica and type 1 collagen not only increased the
cellular Ca phosphate deposition but also stimulated cell
proliferation.234
In addition to biosilica obtained from biosilicifying
organisms, there are also other silicon derivatives with
interest for biomedical interest. Among them, one would
like to highlight the elegant work of Lopez-Alvarez
et al.,262 which describes the preparation of biomorphic
silicon carbide ceramics from marine precursors. In this
work, molten Si is infiltrated in carbon templates, with
interesting microstructure, porosity and pore intercon-
nectivity, obtained by controlled pyrolysis of algae or
marine plants. The resultant product is a light, tough
and high-strength material with predictable microstruc-
ture. Figure 21 shows an example of such material,
derived from the aquatic plant Juncus maritimus, where
can be seen the morphology of the plant after pyrolisis,
before (Fig. 21a) and after (Fig. 21b) silicon infiltration.
In fact, biological structures often exhibited amazing
morphologies that justify all the efforts for biomimetic
approaches to allow its synthetic reproduction. In par-
ticular, biomineralising organisms have such a hierarch-
ical structure, making nature a manufacturer with
which mankind could never compete. In this perspec-
tive, biomimetic approaches to replicate those hier-
archical structures are constantly being explored by
different researchers, such as the one just mentioned
by Lopez-Alvarez et al.262 or the work of Sandhage
et al.263–265 on the use of diatom frustules as templates
for the production of other ceramic structures with
matching morphological features, such as MgO or
BaTiO3. In the work of Sandhage et al., instead of an
20 Electron micrographs representing the two types of diatoms: at left, Thalassiorisa pseudonana, scale bar52 mm; at
right, Nitzschia alba, scale bar55 mm (reproduced from Sandia National Laboratories report SAND2007-6359)
21 SEM images evidencing the morphology of the aquatic plant Juncus maritimus after pyrolisis, before (a) and after (b)
silicon inﬁltration (reprinted with kind permission of Professor Pio Gonza´lez, University of Vigo)
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infiltration process, there is a chemical transformation,
for instance according to equation (2)
2Mg(g)zSiO2(s)R2MgO(s)z{Si} (2)
where {Si} represents a silicon-based product resulting
from the chemical reduction, such as Mg–Si liquid or
Mg2Si.
264,265 This reaction occurs when submitting
diatom frustules, as for instance the ones from
Aulacoseira genre, to heating until 900uC, in the
presence of magnesium. At this temperature, there is
evaporation of magnesium that can thus react in a redox
process with SiO2, without affecting the morphology of
the structure, as illustrated in Fig. 22.263,264 This
structures can be submitted to further treatments to
render other ceramic solids, such as treatments with HCl
solution and ethanol-based hydrofluoric acid solution to
render silicon structures263 (Fig. 22c–f). Another possi-
bility is an additional deposition of a barium titanate
(BaTiO3) layer onto the magnesia solids, using a sol–gel
process,265 resulting in bioclastic-based ceramics with
multicomponent and nanocrystalline features. More-
over, the inclusion of genetic modification steps in order
to render self-replicating structures with defined shapes
is envisaged, taking advantage of the recent genome
mapping and genetic engineering technologies, which
may allow the development of genetically engineered
micro/nanodevices.265
Common applications
Recent screening techniques have revealed a vast
chemical diversity of the oceans, much higher than the
one that can be achieved by synthesis and standard
chemical approaches, which opens new and exciting
research scenarios. In fact, the real value of marine-
derived materials and compounds can only be roughly
imagined as much of sea life, particularly in deep waters,
22 SEM images of a Aulacoseira diatom frustules, b MgO/Si replica obtained after reaction of frustule with Mg at 650uC,
c silicon-based replica produced after treatment with HCl solution and d silicon replica obtained after additional treat-
ment with HF solution. e and f are the results of the energy dispersive X-ray analysis of silicon-based replicas shown
in c and d respectively (reprinted from Ref. 263 with permission from Nature Publishing Group)
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is still to be discovered. Thus, the sustainable exploita-
tion of ocean diversity for industrial and medical
purposes is of enormous interest and promises a huge
impact not only in research, but particularly in the
progress of society, which is reflected on the emergence
of marine biotechnology, also known as blue biotech-
nology, as a fast-growing sector.266,267
For the stated above, though the focus of this review
is to highlight marine biopolymers and ceramics with
interest for biomedical application, it would be unforgi-
vable not to comment on the applications of those
marine materials in other sectors, particularly by
illustration of applications already in use. Thus, this
section will briefly portray the most common applica-
tions of the materials reviewed above, with indication of
bibliographic references where the readers can find
deeper discussions.
Agar possesses a long and ancient history, with its gel-
like properties being alleged to have been first observed
by a Chinese Emperor in the mid-sixteenth century.
Afterwards, a flourishing agar manufacturing industry
was established. The development path of agar closely
follows the appearance and growth of microbiology, as
it was first reported to be used as a bacteriological
culture medium by Koch.27 Over a century, it is still the
medium of choice for general microbiological research.93
Besides its use in the preparation of microbiological
media, agar is usually applied also in cell/tissue culture,
in affinity chromatography, as a component of dental
impression materials, as a raw material for the produc-
tion of agarose or as a gelling agent in food industry,
cosmetics and pharmaceutical products, besides applica-
tions in medicine.23,26,27,93 Although agar does not
possess direct medicinal use, its application in biomedi-
cal research is well known. The industrial and commer-
cial relevance of agar lies on its excellent thickening and
gelling properties.
The history of alginate starts in 1881, when it was
discovered by Stanford, followed by a patent where
Stanford claims the application of alginate as a
pharmaceutical agent. In 1929, Kelco Co. starts to
commercialise this polysaccharide, extracted from kelp,
also known as the giant brown seaweed, Macrocystis
pyrifera. In 1959, alginate had evolved to a worldwide
production.43 Nowadays, alginate is widely used as a
gelling agent for different applications, namely, in the
food industry, pharmaceutical, biomedical and personal
care.42,268,269 The success of commercial development of
alginate lies in its ability to retain water, and in its
gelling, viscosifying and stabilising properties, in parti-
cular the fact that it increases the viscosity of aqueous
solutions and forms gels without temperature depen-
dence, in contrast with other polysaccharides like agar
and carrageenan.45 Other biotechnological applications
can take advantage of the specific biological effects of
alginate, like hypocholesterolemic and hypolipidemic
effects.270 It is then expected that future expansion of
alginate market will be through more knowledge-
demanding areas, such as pharmacy, biotechnology
and biomedicine.
Carrageenan is another family of polysaccharides that
find application in very different sectors of activity,
including slurry stabilisation and suspension, interac-
tion with polyols, and entrapment/immobilisation of
enzymes or microbial cells in fermentation processes at
industrial level,271 dentifrice preparations, anti-icers,
cosmetics, pharmacological excipient,272 capsules,273
hydrogels274 and films,275 and texturising agent in food
applications.276,277 In fact, when used in food products
in the European Union, carrageenans are designated by
the reference E407, according to the classification of
food additives, being used in particular as stabilisers,
thickeners and emulsifiers.278 This huge potential of
application of carrageenan in such a broad range of
fields can be weighted by the several thousands of pa-
tents registered using carrageenan in food and non-food
applications.
Chitin, chitosan and its derivatives are widespread in
economical sectors, being used in areas such as agri-
culture, water treatment, food preservation, cosmetic
industry, pharmaceutical and veterinary medicine.279–285
Properties such as antimicrobial activity, film-forming
ability, high adsorption, excellent chelation behaviour,
biocompatibility and non-toxicity have been pointed out
as main responsible by performance of chitosan on the
cited applications.19,286,287 For example, antimicrobial
chitosan films have been used as a packaging material
for a preservation of a variety of foods and antioxidant
in sausages.279,288,289 In agriculture, both chitin and
chitosan have been utilised to enhance the plant innate
defense.282 On the other hand, many works285,290–292
suggested chitosan as an effective biosorbent for the
removal of aquatic pollutants, such as phenol, pesti-
cides, anions, metal ions (zinc, copper, lead and
cadmium) and dyes. Besides, chitosan and its deriva-
tives have been recognised as ingredient for cosmetic
formulations281,293 and have also been studied as
promising materials for biological functionalisation of
microelectromechanical systems294 due to its physical-
chemical properties and the easy integration of chitosan
films in microdevices. In some of those applications,
chitosan needs to be physically or chemically modified
and the current research on the improvement of its pro-
perties is expected to increase the presence of chitosan-
based products on the various segments of the world
market.
Although the attention on the GAG, particularly
from marine origin, is increasing during the last years,
their application or large-scale use is scarce. Never-
theless, a few applications can be identified to illustrate
the huge potential possess of this class of biopolymers.
Marine CS is being studied to explore its potential as a
biomedical gel forming polymer, anticoagulant activity
and as a supplement in arthritis-related diseases.154,295–301
Marine DS is also an object of research to explore its
anticoagulant activity aiming a potential replacement
agent for heparin.295–297,302–307 In fact, the search for new
natural sulfated polysaccharides with relevant antic-
oagulant and antithrombotic action is an attractive
alternative for the traditional heparin use in medicine,
and there are several reports of other sulphated com-
pounds from marine origin, such as heparin and fucans,
also with this aim.152,154,296,308,309
Hyaluronic acid is ubiquitously present in the human
body, namely, in intercellular matrix of most connective
tissues, as thus have found applications mainly in the
biomedical field. In particular, it is used as surgical aid in
ophthalmology and exhibits significant therapeutic
potential in joint disease and wound-healing.310,311 Its
ophthalmological use is based on the semiflexible
Silva et al. Materials of marine origin
International Materials Reviews 2012 VOL 0 NO 0 19
properties of the high molecular weight chains and the
interactions between them, which renders solutions with
unique viscoelastic properties.312 In fact, the most
common application of hyaluronic acid is as a viscoe-
lastic adjunct in patients undergoing cataract surgery.312
Regarding the therapeutic potential in joint disease, its
role for supplementation of impaired synovial fluid in
arthritic patients by means of intra-articular injections is
highlighted.313 Hyaluronic acid has also other clinical
medicine uses, as a diagnostic marker for diseases such
as cancer, rheumatoid arthritis and liver pathologies,313
but also promises application in the surface modification
of titanium orthopedic implants aiming to reduce
bacterial infection and enhance cell adhesion.314
Moreover, its use in cosmetic regeneration and recon-
struction of soft tissue has also been envisaged and
described.312,313 Hyaluronic acid also finds pharmaceu-
tical application, with drug delivery systems being
proposed or already demonstrated.312,315
Being the main protein in mammals, collagen is an
important ingredient for health-related applications, being
used in cosmetics, dental composites, skin regeneration
templates, biodegradable matrices and shields in ophthal-
mology, cardiovascular surgery, plastic surgery, orthope-
dics, urology and neurology.316 However, collagen and
gelatin (denaturated collagen) are also used in very
different sectors, as in food industry, for instance, in
sausage casings made of dispersed insoluble collagen
extruded as a tube and formed or cut into links as it is
filled. Marine collagen in particular is currently being
studied to be used in all the traditional areas where
mammal collagen finds application, to overcome the
abovementioned disease-related issues, as well as in ad-
vanced methodologies for artificial organs, tissue engi-
neering and drug delivery applications.317–320
Besides biopolymers, marine ceramics are also very
interesting for several applications. Calcium phosphates,
despite being used mainly as bioceramics in drug
delivery systems,321 tissue engineering scaffolding, bone
graft substitutes and facial fillers,322,323 have also been
found outside biomedical area but in related fields,
namely as supplements for pharmaceutical and cos-
metics industries, oral care products and jelling
agent.324,325 Besides, it can also be used as an ingredient
is many industrial cements and chemicals.
Another marine ceramic with quite interesting proper-
ties is biosilica, mainly due to the biomineralisation
process. For instance, sponges (phylum Porifera) have a
biosilicification process mediated by enzymes resulting
in silica structures ranging in size from micrometres to
metres, which can be conjugated with polymers such as
collagen to form micro- and nanocomposites. These
structures present an interesting physical stability and an
impressive light transmission capability similar to optic
fibres. These properties have been further explored in
recent years in order to study the development of new
applications for biomedicine, in particular for biosilica-
mediated regeneration of tooth and bone defects, and
for micro-optics, in particular through the in vitro
synthesis of light waveguides.234,235,326 A quite interest-
ing morphology is also observed in diatoms, where the
silica skeleton exhibits symmetric patterns of micro- and
nanopores in which light transmission is found to be, in
some cases, strongly wavelength dependent,327 suggest-
ing their exploitation in biomimetic optical applications,
such as light guiding and optical transducing.328 Besides
the mentioned applications, others are being explored
with silica-based materials, such as the protein–silica
nanocomposites for biosensing applications reported by
Ramanathan et al.329 or silica particles for the develop-
ment of oral drug delivery vehicles reviewed by Rigby
et al.,330 which may enhance the potential for applica-
tion of biosilica in other fields.
Drug delivery applications
Marine-derived materials, especially polysaccharides,
have been widely used in the development of drug
delivery devices, especially with the shape of spheres of
different sizes.331,332
Chitosan and alginate have been probably the most
used marine-derived polymers in the preparation of drug
delivery particles.269,333–340 Chitosan itself may be
chemically modified to control the interaction with drug
molecules. For example, the chemical attachment of
cyclodextrins or amphiphilic molecules to chitosan-
based macromolecules may enhance the affinity of the
polysaccharide with hydrophobic drugs.341,342
Nanoparticles are especially adequate to act as
injectable delivery systems of a variety of therapeutic
molecules. Polysaccharides-based nanoparticles have
been produced by different methods, including covalent
cross-linking, ionic cross-linking, polyelectrolyte com-
plex and the self-assembly of hydrophobically modified
polysaccharides.343 For example, poly(amidoamine)
low-generation dendrimers are surface chemical mod-
ified by carboxymethylchitosan, rendering dendritic
nanoparticles (Fig. 23). These nanoparticles are shown
to be internalised by cells and thus be used in
intracellular drug delivery strategies.344 Using a rational
of electrostatic interactions, chitosan/carrageenan nano-
particles are produced in mild conditions and showed to
permit the encapsulation and posterior release of
proteins.345 Using a equivalent methodology, micropar-
ticles of carrageenan and gelatin, as well as of ulvan and
chitosan, has also been prepared, as illustrated in
Fig. 24. Interactions between polyelectrolytes may be
also used to coat particles or drug crystals or to produce
capsules using the layer-by-layer methodology, as
illustrated by the scheme in Fig. 25. Chitosan or
alginates have been used to produce such multilayered
nanostructured coatings.346–349 Such films are usually
stable in physiological conditions and may act as a
23 TEM image of carboxymethylchitosan/poly(amidoamine)
dendrimer nanoparticles
Silva et al. Materials of marine origin
20 International Materials Reviews 2012 VOL 0 NO 0
physical barrier for the release of the encapsulated
molecules. The permeability can be controlled by
changing the nature of the polyelectrolytes used and
the number of multilayers.
Marine origin polysaccharides have acidic or basic
functional groups. Thus, the ionisation level of the
pendant group changes strongly around the pKa,
causing a modification of the water solubility of the
polymer chains or the swelling in the case of cross-linked
systems. Hydrogels with such characteristics are pH-
responsive and have been proposed for the smart
delivery of bioactive agents.350–352 They are based on
the fact that swelling or degradation will be highly
sensitive to changes in the pH in the body or inside
cells. Systems that can respond simultaneously and in-
dependently to more than one external stimulus, such as
pH and temperatures, have also been developed.352,353
In most of the cases, they are produced by combin-
ing pH-responsive macromolecules and temperature-
sensitive polymers, especially poly(N-isopropyacrylamide),
PNIPAAm, either by grafting or by blending. A possibility
to produce dual-responsive systems is by combining the
two macromolecules by means of interpenetrating or
semi-interpenetrating networks. An example included the
combination of alginate and PNIPAAm where the pH-
responsive polysaccharide was cross-linked with calcium
ions;354 the swelling of the obtained beads were highly
dependent on both temperature and pH, and strong
deviations were also found in the delivery profile of
indomethacin. In order to try to slow down the release
profile, such particles were coated with chitosan, followed
by alginate.355 Such kinds of particles were also partially
mineralised with calcium phosphate in order to poten-
tially improved their biocompatibility with bone tissue:356
the calcified systems were shown tomaintain their pH and
temperature responsiveness, and could be useful in the
delivery of relevant therapeutic agents or in the construc-
tion of scaffolds for orthopedic applications.
Tissue engineering applications
In the general tissue engineering approach, matrices are
developed to support cells, promoting their differentia-
tion and proliferation towards the formation of new and
functional tissue.357 Such strategy allows producing
hybrid constructs that can be implantable in patients
to induce the regeneration of tissues or replace failing or
malfunctioning organs. Different materials have been
proposed to be used in the processing of scaffolds,
namely, biodegradable polymers derived from marine
resources. Natural-based polymers offer the advantage
similar to biological macromolecules, where the biolo-
gical environment is prepared to recognise and to deal
with metabolically. Owing to their similarity with the
extracellular matrix, natural polymers may also avoid
the stimulation of chronic inflammation or immunolo-
gical reactions and toxicity, often detected with synthetic
polymers. The sea may be an important source of
materials to be used in such applications, in which a
variety of polysaccharides with different chemical
natures, proteins and minerals can be found.
An important aspect is the processing of such kind of
materials into porous matrices, a task that usually needs
other technologies than those usually employed in the
processing of conventional synthetic polymers that often
implies the melting of the material or the use of organic
solvents.358 Mild methods have been widely used to
process marine-derived polymers that may be also
attractive by the fact that cells or unstable proteins can
be incorporating during the fabrication of the device.
Freeze–drying has been widely used to process natural
polymers, including marine-derived polysaccharides. A
classic example is the production of scaffolds from
chitosan:73 acidic aqueous solutions are frozen and
lyophilised and the final scaffold is neutralised and
stabilised in an alkaline solution and water, rendering
structures like the one depicted in Fig. 26a. Figures 26b
and c show the morphology of the produced scaffold
with higher detail, using SEM and microcomputed
tomography. The structure of the final scaffold will
essentially depend on the initial chitosan concentration
and on the shape and size of the ice crystals generated
during the freezing step. Cross-linking or the incorpora-
tion of other biomacromolecules can be also combined
with such method.359 For orthopedic application, such
scaffolds can be incorporated into more stiff pre-
fabricated scaffolds360 or can also be combined with
inorganic bioactive particles,361,362 including marine-
derived ceramics.363 Such osteoconductive scaffolds
24 SEM images of microparticles of a carrageenan and gelatin and b ulvan and chitosan, prepared by ionic interaction
between polymers
25 Cartoon of the methodology to prepare polyelectrolyte
capsules: a coating of a colloid with polyelectrolyte
multilayers; b nucleolus decomposition; c nucleolus
residues leave the system through the multilayered
membrane, rendering a capsule
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containing chitosan-derivatives may be also produced by
precipitation-related methodologies.364 Another method
to fabricate macrofibres from chitosan-containing solu-
tions is by wet-spinning where the polymer from a solution
filament is continuously precipitated into a coagulation
bath.77,365 Chitosan solutions can be also precipitated into
spheres that may be used in tissue engineering, either by
agglomerating them into scaffolds76,366 producing struc-
tures like the ones shown in Fig. 27, or use them directly
with cells as an injectable system.367 Matrices for regene-
rative medicine may be also produced using electrospin-
ning, which enables to produce non-woven supports made
of nanofibres, for example, using polysaccharides.368
Such technology has been used to produce nanofibres
of marine-derived materials such as chitosan,369,370
alginate371 or even materials containing marine-derived
collagen.372
Complexation of polysaccharides with oppositely
charges, such as chitosan and alginate, may be also
used to produce scaffolds.373 For example, by using
spray-spinning, a chitosan solution was sprayed into a
flowing sodium alginate solution and sheared into
streamlines – the elongated streamlines subsequently
transformed into alginate/chitosan polyelectrolyte com-
plexes fibres.374
The ability of alginate to cross-link with calcium ions
may be also used to produce scaffolds.375 The calcium
source may be even from hydroxyapatite allowing to
process nanocomposite porous structures.376 However,
alginates have been much more used in tissue engineer-
ing as non-porous structures, as cells may be easily
encapsulated during the hydrogel formation.377,378
Alginate molecules have been modified by incorporating
RGD sequences along the macromolecular structure, in
order to enhance the specific interaction with cells – such
systems may be used as injectable systems in which cells
may act as cross-linking entities.379,380 Moreover, ionic
cross-linking can be also used with other polymers, such
as carrageenans, preparing organised structures aimed
for cell culture, by rapid prototyping, through extrusion
of carrageenan solution from a syringe into a coagula-
tion bath. Figure 28 illustrates the structures that can be
produced with such technique.
Injectable systems are very attractive as they can
deliver and fix cells and molecules in specific sites in
the body using minimally invasive methods.381,382 The
materials may harden in situ from different ways,
including through ionic, hydrogen or covalent bonds.
Thermoreversible gels are very popular as such system
may exist in a liquid state at room temperature but turn
into a self-sustained gel at body temperature.383 An
interesting example is the chitosan/b-glycerolphosphate
systems: in 2000, Chenite and co-workers developed
such kind of formulations to produce an injectable
thermosensitive, pH-dependent solution, which is liquid
at physiological pH and room temperature, and
becomes a gel if heated at body temperature.384 Such
materials may be combined with bioactive glass–ceramic
particles to produce biodegradable injectable osteocon-
ductive biomaterials.385 Higher contents of calcium
phosphates may be incorporated in chitosan to produce
composites bioresorbable cements able to be replaced by
new bone.386
Other marine-derived materials have been developed
to produce injectable systems for tissue engineering,
such as carrageenan – this polysaccharide, combined
with fibrin/hyaluronic acid, may have potential in car-
tilage regeneration.387 Alginate-based injectable hydro-
gels have also been proposed for such applications388 or
for cardiac remodeling.389 The main drawback of such
26 Photo of freeze–dried and neutralised chitosan scaffold (a) and respective SEM image (b) and microcomputed tomo-
graphy image (c)
27 Photos of (a) chitosan particles prepared by precipitation of droplets of chitosan solution into an alkaline coagulation
bath, which can be agglomerated forming a porous structure (b)
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biomaterials will be always limited by the mechanical
properties – further developments are required to enhance
the cross-linking extent and stability and the incorpora-
tion of other strategies to enhance the stiffness and
strength of the hydrogels in physiological conditions.
Besides polysaccharides, other marine-derived biopo-
lymers are also being used on tissue engineering strategies,
as collagen. Being the main protein in the body, collagen
is a biomaterial for excellence and a relevant choice when
one wants to develop a tissue engineering scaffold. In this
perspective, marine-derived collagen scaffolds were devel-
oped by freeze–drying using jellyfish collagen, further
cross-linked, which did not induce a significant cytotoxic
effect and had higher cell viability than other biomater-
ials, including bovine collagen. Moreover, in vivo tests
demonstrated that jellyfish collagen induced a comparable
immune response to that induced by bovine collagen.187
Jellyfish collagen has also been combined with poly(lactic-
co-glycolic acid) and processed by freeze–drying and
electrospinning to obtain tubular scaffolds, in which
smooth muscle cells and endothelial cells were shown to
proliferate.372 Taken together, these results support the
great potential of marine origin collagen for tissue
engineering applications.
Concluding remarks and future outlook
Sea has proven to be a huge source of materials, even
though the available knowledge of marine materials and
mechanism are still in its beginning. Nevertheless, with
the technological development, such as the appearance
of new remotely operated (underwater) vehicles that
allow collection of materials in deep waters, an
enormous new door is being open. In fact, marine
biomaterials are of particular interest as they might have
novel characteristics as well as unique biochemical
properties. Moreover, the diversity of these materials
and its potential, in particular of polysaccharides, can be
increased by physical or chemical modifications, like
complexation with other polymeric materials, chemicals
or salts or modifications introduced in the polysacchari-
dic chain. The possibility of developing a wide variety of
chemically modified derivatives makes these polysac-
charides versatile materials that can be applied in
different fields of technological interest, including the
biomedical one. This is a continuing challenge to
polymer and biomaterial scientists, but it is already
possible to anticipate that these strategic approaches will
widen up perspectives and potential applications in the
future. On the other hand, this will render low
environmental impact products that have a lower
carbon footprint at the end of product cycle. The
enhancement of the performance of marine-derived
polysaccharides will increase their competitiveness
against synthetic biodegradable polymers and polymers
from petroleum sources. In an era of increasing oil
prices, global warming and other environmental pro-
blems (e.g. waste), the change from fossil feedstock to
renewable resources can considerably contribute to a
sustainable development in the future.
It is envisaged that biomedical field will be an area in
which marine-derived materials will have a role of major
relevance, in particular with their use on tissue repair
and regeneration. This multidisciplinary approach that
aims to go from engineered scaffolds to clinical
applications that allow regeneration of damaged or
injured tissues or organs is not that fair to accomplish its
goals and marine-derived materials are being increas-
ingly studied. However, strong efforts are still needed to
obtain medical grade biopolymers from marine raw
materials, in a reproducible way, to allow its use on the
development of three-dimensional scaffolds in which
different cells can be seeded and then proliferate,
rendering a new tissue that can be implanted in the
patient. In addition, the use of marine origin materials in
tissue engineering approaches, in particular their success
in in vivo testing, is still needed to boost their potential in
this area. Nevertheless, this is a route that is being
followed together with other materials by tissue engi-
neers to turn biomaterial-based regenerative medicine
into a real clinical solution.
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